Bioceltix Sa · GPW:BCX
Bioceltix Sa — Investor Presentation (December 2025)
8 slides from Bioceltix Sa's investor presentation, Dec 10, 2025
Slide 1: More than animals. More than technology.
More than animals. More than technology.
Slide 2: Veterinary biotechnology: Cutting-Edge Stem Cell-Based Therapies
Veterinary biotechnology : Cutting-Edge Stem Cell-Based Therapies stem-cell-based therapies medicines to treat inflammatory and autoimmune diseases in companion animals. Let’s dive into: • Rising opportunities driven by the growing market for veterinary biological drugs and social trends • first-of-
Slide 3: Adipose-derived stem cell-based medicines
Adipose-derived stem cell-based medicines 3 Immunomodulatory Mesenchymal properties Large scale GMP stem cells production facility as an Active with clear and Pharmaceutical Allogeneic cell Ingredient simple approach for further upscaling therapy Waste-derived adipose tissue as a source (donor) mate
Slide 4: Osteoarthritis in dogs
Clinically proven OSTEOARThritis in dogs Safety and Efficacy 4 chronic pain Therapeutic effect demonstrated both in #1 cause in dogs short (30 days) and long (90 days) term after a single administration of BCX-CM-J dogs Improvement in joint pain and lameness 20% affected (assessed by a veterinarian)
Slide 5: Atopic Dermatitis in dogs
Clinically proven ATOPIC Dermatitis in dogs Safety and Efficacy 5 BCX-CM-AD Single intravenuos administration of BCX-CM-AD significantly reduced skin 15% Dogs affected lesions after 28 days and pruritus after 56 days Causes pruritus, infections, S K I N LE S I O NS external otitis CADESI-4 scale (ve
Slide 6: Osteoarthritis in horses
Clinically proven 6 Osteoarthritis in horses Safety and Efficacy BCX-EM Therapeutic effect demonstrated both in mid (28 days) and long (42 days) term after a single administration of BCX-EM Cause of lameness and pain #1 in horses Reduction of lameness most riding based on AAEP score based on flexion
Slide 7: New Production Facility
NEW PRODUCTION FACILITY 7 Allogeneic approach : Multiplied donor cells can go to many other individuals of the same species, regardless of the race Current production PRODUCTION SCALE-UP The launch of new facility in second half of 2026 10 – 12 production campaigns per • Localized in Wroclaw on 1300
Slide 8: Bioceltix
Bioceltix ay,